What is the future of Mpox outbreak?

IF 2.4 3区医学 Q3 VIROLOGY

Virology Pub Date : 2025-06-27 DOI:10.1016/j.virol.2025.110618

Grace Naswa Makokha, Maidina Abuduwaili, Kazuaki Chayama, Makoto Hijikata

{"title":"What is the future of Mpox outbreak?","authors":"Grace Naswa Makokha, Maidina Abuduwaili, Kazuaki Chayama, Makoto Hijikata","doi":"10.1016/j.virol.2025.110618","DOIUrl":null,"url":null,"abstract":"<div><div>Mpox (formerly known as monkeypox) is a viral zoonotic disease caused by the Mpox virus, which belongs to the <em>Orthopoxvirus</em> genus, in the same family as the variola virus which causes smallpox. Although Mpox was historically confined to Central and West Africa, the 2022 global outbreak marked a significant shift, with cases reported in non-endemic countries but through a combination of targeted public health interventions, vaccination efforts, and behavioral changes within affected communities, the outbreak was brought under control by late 2022 in many regions outside Africa. However, since 2023 a resurgence of the disease in parts of Central and West Africa, driven by the Clade Ib variant, has raised fresh concerns. The outbreaks have been exacerbated by limited diagnostic infrastructure and healthcare access, which prompted the World Health Organization (WHO) to declare a public health emergency regarding this variant in mid-2024. This review aims to explore the future of Mpox outbreak by analyzing the current understanding of the virus, the challenges experienced in handling it, and areas requiring further investigation.</div></div>","PeriodicalId":23666,"journal":{"name":"Virology","volume":"610 ","pages":"Article 110618"},"PeriodicalIF":2.4000,"publicationDate":"2025-06-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Virology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0042682225002314","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"VIROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Mpox (formerly known as monkeypox) is a viral zoonotic disease caused by the Mpox virus, which belongs to the Orthopoxvirus genus, in the same family as the variola virus which causes smallpox. Although Mpox was historically confined to Central and West Africa, the 2022 global outbreak marked a significant shift, with cases reported in non-endemic countries but through a combination of targeted public health interventions, vaccination efforts, and behavioral changes within affected communities, the outbreak was brought under control by late 2022 in many regions outside Africa. However, since 2023 a resurgence of the disease in parts of Central and West Africa, driven by the Clade Ib variant, has raised fresh concerns. The outbreaks have been exacerbated by limited diagnostic infrastructure and healthcare access, which prompted the World Health Organization (WHO) to declare a public health emergency regarding this variant in mid-2024. This review aims to explore the future of Mpox outbreak by analyzing the current understanding of the virus, the challenges experienced in handling it, and areas requiring further investigation.

查看原文本刊更多论文

麻疹疫情的未来是什么？

m痘（以前称为猴痘）是由m痘病毒引起的病毒性人畜共患疾病，该病毒属于正痘病毒属，与引起天花的天花病毒属于同一科。虽然Mpox历来局限于中非和西非，但2022年的全球暴发标志着重大转变，在非流行国家报告了病例，但通过有针对性的公共卫生干预措施、疫苗接种工作和受影响社区内的行为改变相结合，到2022年底，疫情在非洲以外的许多地区得到了控制。然而，自2023年以来，该疾病在中非和西非部分地区重新抬头，由进化枝Ib变体驱动，引发了新的担忧。有限的诊断基础设施和医疗保健服务加剧了疫情，这促使世界卫生组织（世卫组织）在2024年年中宣布这一变种进入公共卫生紧急状态。本综述旨在通过分析目前对该病毒的认识、处理该病毒所面临的挑战以及需要进一步调查的领域，探讨麻疹疫情的未来。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Virology 医学-病毒学

CiteScore

6.00

自引率

0.00%

发文量

157

审稿时长

50 days

期刊介绍： Launched in 1955, Virology is a broad and inclusive journal that welcomes submissions on all aspects of virology including plant, animal, microbial and human viruses. The journal publishes basic research as well as pre-clinical and clinical studies of vaccines, anti-viral drugs and their development, anti-viral therapies, and computational studies of virus infections. Any submission that is of broad interest to the community of virologists/vaccinologists and reporting scientifically accurate and valuable research will be considered for publication, including negative findings and multidisciplinary work.Virology is open to reviews, research manuscripts, short communication, registered reports as well as follow-up manuscripts.